GlassScriptPhysician profile
Shilpi Relan
NPI 1699018721
$1,664.26
in general payments reported to CMS, 2019-2025
18 companies · $766 in 2025
The $766 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.07 · 2021: $18.61 · 2022: $37.73 · 2023: $323 · 2024: $508 · 2025: $766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,596.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $290.50 | 2023-2025 | |
| Novo Nordisk INC | $189.32 | 2023-2025 | Sogroya, Wegovy |
| Medtronic, INC. | $152.53 | 2023 | Minimed 780g |
| Ascendis Pharma Endocrinology INC | $143.15 | 2022-2025 | Skytrofa |
| Alexion Pharmaceuticals, INC. | $138.30 | 2021-2025 | Strensiq |
| Sanofi-Aventis U.S. LLC | $109.09 | 2023-2025 | |
| Insulet Corporation | $101.73 | 2023-2025 | Omnipod |
| Pfizer INC. | $97.45 | 2024-2025 | |
| Tolmar, INC. | $88.74 | 2023-2025 | Fensolvi |
| Kyowa Kirin, INC. | $77.55 | 2023-2025 | Crysvita |
| Abbott Laboratories | $48.07 | 2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Dexcom, INC. | $40.71 | 2024-2025 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $40.29 | 2025 | |
| Endo USA, INC. | $35.27 | 2024-2025 | Supprelin |
| Biomarin Pharmaceutical INC. | $34.39 | 2024-2025 | Voxzogo 1.2mg |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $31.78 | 2020-2022 | |
| Eton Pharmaceuticals, INC. | $31.71 | 2025 | Increlex, Alkindi, Khindivi |
| Azurity Pharmaceuticals, INC. | $13.68 | 2024 | Triptodur |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shilpi Relan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.